Alnylam (ALNY) Q3 2026 Earnings Call Transcript

Alnylam (ALNY) reported Q3 2026 revenue of $1.46B, up 17% YoY, driven by TTR franchise growth. AMVUTTRA sales rose 65% YoY to $1.13B. Guidance for TTR product sales was lowered to the range of $4.2B-$4.5B. Management cited Medicare Advantage policy changes and 340B reimbursement adjustments as risks. TRITON-CM study enrollment target was expanded to 2,250 patients.

Original reporting
Published Oct 29, 2026, 4:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alnylam (ALNY) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ALNYBearishHigh
01

Why it matters

The earnings release provides fresh quantitative data and forward guidance, creating immediate trading relevance.

02

Market read

First‑report earnings with material numbers and guidance, likely to move the stock in the short term.

03

What to watch

Potential upside from upcoming Huntington's disease trial data and possible new collaborations.

Relevance 8/10Novelty 8/10Timing: after market close

Background

Alnylam Pharmaceuticals presented its Q3 2026 earnings, highlighting revenue growth, product performance, and guidance.

Company-level read

Ticker impact

$ALNYBearishHigh confidence
Context

Q3 2026 earnings call disclosed $1.46B revenue, 17% YoY growth, and full‑year TTR product revenue guidance of $4.2‑$4.5B.

Expected impact

likely modest downside as investors price in lower‑end guidance and Medicare Advantage restrictions.

Evidence & confidence

The company reported strong sales growth yet trimmed outlook and highlighted payer‑risk, which historically triggers short‑term price pressure.

Market effects

Biotech sector may see heightened scrutiny on payer‑risk for rare‑disease therapies.

U.S. biotech stocks could face slight pressure in the near term.

Limited; impact confined to investors tracking RNAi therapeutics.

Counterpoint

Despite payer‑risk comments, the strong product revenue growth could support upside if guidance is revised upward later.

Key entities

  • Alnylam Pharmaceuticals

    US‑listed biotech firm (ticker ALNY) reporting Q3 2026 results.

Related articles

$ALNYHighAI 8/10

Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today

Alnylam Pharmaceuticals (ALNY) stock rose 6.9% after the company shared positive long-term data for AMVUTTRA, reinforcing its cardiovascular benefits. The company also reiterated 2026 guidance and authorized a $1 billion share repurchase program, signaling confidence. Insider and institutional trading activity was noted, with mixed positions.